Under the Skin: What Subcutaneous Isatuximab Means for Myeloma Care

Matthew Lei, PharmD, BCOP, a clinical oncology pharmacist at Massachusetts General Hospital, joins Pharmacy Focus: Oncology Edition to break down the FDA approval of subcutaneous isatuximab-irfc via the CirCLIQ on-body injector, covering the IRAKLIA trial's noninferiority data, the device's practical rollout challenges, and how the agent positions against subcutaneous daratumumab in an increasingly crowded anti-CD38 landscape.